the HUB provides access to a unique and robust platform that links patient-specific genetic and phenotypic information to preclinical and clinical drug-responsiveness.

Hy2Care develops a so called “injectable plaster” to repair the cartilage surface.

At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.

Immunara is designing nanobody-based carriers that bind to CD169 and deliver a variety of antigen formats, such as recombinant proteins, peptides, viral vectors or RNA.

At IMPACT, they create a therapy that combines patient-derived chondrons with off-the-shelf allogeneic mesenchymal stromal cells (MSCs), enabling regenerative treatment in a single surgery. This reduces both patient burden and hospital costs compared to current cell therapies.

Injectable bone filler with drug release function for treatment of bone infections (INBORN)

Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Liquid biopsy platform for purification and collection of intact CTCs directly from blood

An infusion set that guarantees stability and immediacy of drug administration for preterm babies